Search Results
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
mg ASC30 tablets or placebo. The primary objective of the study was to demonstrate superiority of ASC30 once-daily tablets (20 mg, 40 mg, 60 mg) to placebo in body weight reduction from baseline after 13 weeks of treatment. All participants in the ASC30 cohorts started the study at a dose of ASC30 tablets
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 04:40 ET 歌禮口服小分子GLP-1藥物ASC30在肥胖或超重受試者中進行的美國13周II期研究顯示經安慰劑校正後的體重下降高達7.7%，且胃腸道耐受性更佳
kg/m2。80.0%接受60毫克每日一次ASC30治療的受試者體重下降≥5%，而安慰劑組為4.2%；45.0%接受60毫克每日一次ASC30的受試者體重下降≥7%，而安慰劑組為4.2%。除了實現具有統計學顯著性和臨床意義的體重下降外，ASC30也達到了次要和探索性終點。ASC30在所有劑量組中均降低了多項已知的心血管風險標誌物，包括總膽固醇、低密度脂蛋白膽固醇（LDL-C）、甘油三酯以及收縮壓和舒張壓。在穩態下，ASC30的血藥濃度隨劑量增加而增加。每周滴定（titrated weekly）直至目標劑量的ASC30的嘔吐發生率約為已公佈的每周滴定的orforglipron中觀察到的嘔吐發生率的一半（表1）。每周滴定的ASC30的胃腸道耐受性與已公佈的orforglipron在III期ATTAIN-1研究中每四周滴定（titrated
More news about: 歌禮製藥有限公司
Dec 03, 2025, 17:31 ET Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
including Novo Nordisk (Mim8, ALHEMO), Sangamo Therapeutics (Giroctocogene fitelparvovec), Roche/Chugai (NXT007), ASC Therapeutics (ASC-618), Ultragenyx (DTX201), and others.Hemophilia A Market AnalysisThe primary goal of current treatment strategies
More news about: DelveInsight Business Research, LLP
Dec 03, 2025, 10:47 ET Davie Defense Closes Gulf Copper Acquisition, Confirming U.S. Shipbuilding Expansion
process and to working with the U.S. Coast Guard to determine how best to advance the Arctic Security Cutter (ASC) project in America. Davie Defense is in negotiations to deliver five ASCs. The ASC is based on a proven fourth-generation polar icebreaker design from Helsinki Shipyard, the world's premier
More news about: Davie Defense
Dec 03, 2025, 10:00 ET Florida Cancer Specialists & Research Institute Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders
malignancy characteristics, clinical outcomes, and precursor statesAsciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)
More news about: Florida Cancer Specialists & Research Institute
Dec 03, 2025, 07:00 ET Shoulder Innovations Announces Strategic Partnership with INS to Introduce a Robotic Platform for Shoulder Arthroplasty
Partnership will Expand Shoulder Innovations' Disruptive Ecosystem with Advanced Enabling Technology, Complementing Surgeon and Patient Needs in the ASC Management to Participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference Today at
More news about: Shoulder Innovations
Dec 02, 2025, 16:05 ET Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-pivotal-phase-3-results-of-ziihera-zanidatamab-hrii-combinations-in-first-line-her2-positive-locally-advanced-or-metastatic-gastroesophageal-adenocarcinoma-at-the-2026-asco-gastrointestinal-cance-302630956.htmlSOURCE
More news about: Jazz Pharmaceuticals plc
Nov 30, 2025, 05:15 ET Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
studies.- ASC37 oral tablets' drug exposure, as measured by the area under curve (AUC), was approximately 57-fold of retatrutide's drug exposure in head-to-head NHP studies.- Average observed half-life of ASC37 oral
More news about: Ascletis Pharma Inc.
Nov 30, 2025, 05:15 ET 歌禮選定其首款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨床開發
歌禮制藥有限公司（香港聯交所代碼：1672，簡稱「歌禮」）宣布已選定其首款口服GLP-1R/GIPR/GCGR[1]三靶點激動劑多肽ASC37口服片作為臨床開發候選藥物。歌禮預計將於2026年第二季度向美國食品藥品監督管理局（FDA）遞交ASC37口服片治療肥胖症的新藥臨床試驗申請（IND）。 ASC37口服片是本公司首款利用其專有的口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT）研發而成的腸促胰素（incretin）候選藥物。ASC37是一款利用歌禮基於結構的AI輔助藥物發現（Artificial Intelligence-Assisted Structure-Based Drug Discovery，AISBDD）技術自主發現並優化的GLP-
More news about: 歌禮製藥有限公司
Nov 26, 2025, 09:19 ET George Raymond Zage Ill and James Fu Bin Lu Respond to Grindr Special Committee decision to Cease Engagement on Proposed Take-Private Transaction
www.sec.gov) and from the Company.Media Contacts Steve Bruce / Taylor IngrahamASC [email protected] /
More news about: George Raymond Zage III & James F. Lu
Nov 25, 2025, 16:02 ET CleanSpark Reports Transformative FY 2025 Results
September 30, 2025 and 2024, respectively, which we now record in our Consolidated Statements of Operations and Comprehensive Income as provided in ASC 350-60, as discussed in the Gain on fair value of bitcoin, net section above.Investor Relations Contact Harry
More news about: CleanSpark, Inc.
Nov 25, 2025, 16:01 ET AUTODESK, INC. ANNOUNCES FISCAL 2026 THIRD QUARTER RESULTS
subscription, services, and maintenance for which the associated deferred revenue has not been recognized. Under FASB Accounting Standards Codification ("ASC") Topic 606, unbilled deferred revenue is not included as a receivable or deferred revenue on our Consolidated Balance Sheet. Safe Harbor
More news about: Autodesk, Inc.
Nov 24, 2025, 09:00 ET PathKeeper Surgical Achieves Outpatient Milestone, Validating Radiation-Free Navigation in ASC
is a powerful tool that can be utilized in the ASC to potentially improve the safety and efficacy of spine surgery by giving us the highest level of accuracy while streamlining workflow. PathKeeper elevates the standard of care we can deliver in the ASC."About PathKeeper: PathKeeper
More news about: PathKeeper
Nov 20, 2025, 16:00 ET Webull Reports Third Quarter 2025 Financial Results
considered customers under ASC 606, Revenues from Contracts with Customers ("ASC 606"), and promotional payments made to these platform users are accounted for as a marketing and branding expense. Conversely, for our platform users who have been determined to be customers under ASC 606, we account for
More news about: Webull Corporation
Nov 20, 2025, 16:00 ET Webull Reports Third Quarter 2025 Financial Results
considered customers under ASC 606, Revenues from Contracts with Customers ("ASC 606"), and promotional payments made to these platform users are accounted for as a marketing and branding expense. Conversely, for our platform users who have been determined to be customers under ASC 606, we account for
More news about: Webull Corporation
Nov 20, 2025, 08:03 ET RightRev Unveils Industry's First Unified Lessor Accounting Product Integrated With Revenue Recognition Automation
This unified solution is the first to build complex ASC 842/IFRS 16 lessor accounting capabilities natively inside a market-leading ASC 606/IFRS 15 revenue engine, resolving a critical compliance gap at the core of the hardware XaaS model faced
More news about: RightRev
Nov 20, 2025, 07:00 ET RTX's Collins Aerospace and the Royal Netherlands Air and Space Force establish new military avionics service center
as part of its global military services network. "Bringing our avionics repair capabilities to the RNLASF Air Support Command (ASC) military base will create substantial operational, logistical and sustainment improvement for our European customers," said Brian Barta, vice president
More news about: RTX
Nov 20, 2025, 06:05 ET transcosmos releases "trans-ASC," solution to maximize Meta ad performance
challenge, transcosmos deployed trans-ASC to limit ads to certain age groups with extremely low registration rates. trans-ASC achieved a significant result, increasing the conversion rate and boosted the valid registration rate by 151%. ■ About trans-ASCAdvantage+ sales campaigns
More news about: transcosmos inc.
Nov 20, 2025, 05:33 ET DealHub Expands Revenue Orchestration with Subskribe Acquisition
bandwidth. Auditable Financial Accuracy The platform's built-in ASC 606 and IFRS 15 compliance engines automate the complex calculations that typically require armies of accountants and consultants. Revenue waterfalls,
More news about: DealHub
Nov 20, 2025, 05:05 ET transcosmos wins the Vertical New Hero - Real Estate at Meta Agency First Awards Japan 2025
client, consistently staying up to date with the latest advancements. Building on these insights, transcosmos developed its proprietary solution, trans-ASC, leveraging Meta's AI solutions—its primary focus—to help clients achieve measurable performance enhancements through optimized operations tailored
More news about: transcosmos inc.
Nov 20, 2025, 05:00 ET Vipshop Reports Unaudited Third Quarter 2025 Financial Results
and cash flows for the period presented and the detailed footnote disclosures required by Accounting Standards Codification 270, Interim Reporting ("ASC270") have been omitted. Vipshop uses non-GAAP net income attributable to Vipshop's shareholders, non-GAAP net income attributable to Vipshop's shareholders
More news about: Vipshop Holdings Limited
Nov 19, 2025, 16:30 ET NUTEX HEALTH REPORTS SEPTEMBER 30, 2025 THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance. Adjusted EBITDA is not intended to serve
More news about: Nutex Health, Inc.
Nov 19, 2025, 08:00 ET DealHub Acquires Subskribe, Extending its Leadership in Agentic Quote-to-Revenue
ramps and bundles. Financial accuracy & compliance - Precise billing, tax, and automated ASC 606/IFRS 15 RevRec with audit trails and SOX-friendly controls. Real-time revenue visibility &
More news about: DealHub
Nov 18, 2025, 18:59 ET NUTEX HEALTH REPORTS JUNE 30, 2025 SECOND QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
Beginning in the first quarter of 2025, we updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance. Adjusted EBITDA is not intended to serve
More news about: Nutex Health, Inc.
Nov 18, 2025, 18:50 ET NUTEX HEALTH REPORTS RESTATED FIRST QUARTER 2025 FINANCIAL RESULTS
the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance. Adjusted EBITDA is not intended to serve
More news about: Nutex Health, Inc.